Nothing Stopped This Purchaser from Finding $2.7M in Rx Overpayments
Looking back at our February Pharmacy Benefits forum, we know it’s crucial to keep the momentum up. WHA is going deeper on PBM contracting and negotiation through 2027.
A Washington public employer found $2.7 million her plan had overpaid on generic drugs, about 39% too much on roughly $6 million of generic spend. Nothing had stopped her team from finding it earlier. No law changed and no vendor confessed; they learned where to look, and it took about eighteen months of webinars, free federal reports, and nights reading their own claims data. Speaking at our February forum, she said the right help would have cut that timeline considerably. Giving those eighteen months back to our members is what we are trying to do.
Your contract can be fully transparent and completely useless
Another panelist that joined us earlier this year put it best. Say he tells you there is money hidden in his house and whatever you find is yours to keep. Every word is true, but you are still standing in his hallway wondering whether to look behind the records or under the ice cube trays.
They thought it had a solid contract until its attorney found the discount guarantees applied in aggregate, a quiet way of saying the PBM could overperform on one drug, gouge on another, and still hit every number on the page.
That aggregate math is how a single generic ends up priced the way it did. The February employer’s old PBM charged $291 per day supply for imatinib, the generic form of Gleevec, while a publicly posted cost-plus price list had the same drug at $1.34. All of it disclosed, all of it legal, and all of it costing millions.
Nobody is coming to save you
A panelist who works federal PBM policy said that from our stage, and named why so many purchasers stay put: most employers badly underinvest in their benefits teams, so a plan covering ten thousand employees often runs on two or three staff. Stretched that thin, re-upping with the incumbent stops being a decision and becomes a default.
Congress passed the Consolidated Appropriations Act, 2026 in February, and its commercial market PBM provisions take effect January 1, 2029 for calendar year plans. When they do, plans with at least 100 employees get reports every six months, or quarterly on request, showing drug-level detail on what the plan paid the PBM, what the PBM paid the pharmacy, and every rebate and fee in between. That is more data arriving, which is not the same thing as transparency, and neither one is expertise. The February employer already had her claims data. What she lacked was someone who could tell her which questions it would answer.
What comes next
Our Community Checkup 2026 shows why we keep returning to pharmacy spend. Washington employers absorbed an 8% increase in commercial health care costs in 2024, while prescription drug spending rose nearly 20% year over year. Across more than 4 million covered lives, pharmacy is the sharpest pressure point in the data, and no single employer negotiates its way out of that alone.
That is why WHA is going deeper on PBM contracting and negotiation through 2027, with targeted, interactive work rather than another webinar you half-watch. Every member is welcome, and we build the sessions for the people who sign the contracts.
The employer in this story learned none of it from her consultant, but from other purchasers further down the road who told her which conflicts of interest to look for. Putting our members in that room together is the point, because members who understand these contracts advocate harder for their employees and hold on to real money in their Rx spend. Nobody handed her that $2.7 million. She went and found it.